Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. (May 2010)

• Record Type: Journal Article
• Authors: Bouchlaka, Myriam N; Redelman, Doug; Murphy, William J
• Is Part Of: Immunotherapy. Volume 2:Number 3(2010)
• Page Start: 399
• Page End: 418
• Publication Date: 2010-05
• Subjects: adoptive immunotherapy -- antigen-presenting cell -- graft-versus-host disease -- graft-versus-leukemia -- graft-versus-tumor -- hematopoietic stem cell transplantation -- myeloablative conditioning -- natural killer cell -- nonmyeloablative conditioning -- regulatory T cell; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt.10.20
• Languages: English
• ISSNs: 1750-743X

Abstract

Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.